The settlement removes near-term overhang from this specific ANDA filer but establishes a clear generic entry timeline for DOJOLVI. Monitor progress of remaining ANDA litigations and any FTC/DOJ challenge to the settlement. The 2033 generic entry date is distant, so near-term revenue impact is minimal, but the settlement signals that patent protection may not extend beyond that window.
Price Chart
Executive Summary
Ultragenyx settled patent litigation with Esjay Pharma over generic DOJOLVI (triheptanoin). Esjay gets a non-exclusive, royalty-free license to market its generic version starting January 1, 2033 (extended to July 1, 2033 if pediatric exclusivity is granted). The settlement removes near-term generic risk but sets a definitive loss of exclusivity date, while litigation against other ANDA filers remains pending. No financial terms were disclosed, and the agreement is subject to FTC/DOJ review.
Key Facts
- Ultragenyx settled DOJOLVI patent litigation with Esjay Pharma on August 7, 2026.
- Esjay receives a non-exclusive, royalty-free license to market generic DOJOLVI starting January 1, 2033 (or July 1, 2033 if pediatric exclusivity is granted).
- Litigation against other ANDA filers for DOJOLVI remains pending in the District of New Jersey.
- The settlement agreement will be submitted to the FTC and DOJ as required by law.
- No financial terms of the settlement were disclosed.
Financial Impact
No financial terms disclosed; settlement removes litigation uncertainty but establishes a definitive generic entry date of January 1, 2033 (or July 1, 2033 with pediatric exclusivity).
Risk Factors
- Remaining ANDA litigations could result in earlier generic entry if not settled on similar terms.
- FTC or DOJ could challenge the settlement agreement as anticompetitive.
- Loss of exclusivity for DOJOLVI in 2033 will materially reduce revenue from the product.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-343525 |
| Document: 0001193125-26-343525-index.html | 0001193125-26-343525 |
| Document: 0001193125-26-343525.txt | 0001193125-26-343525 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $14.85 $15.22 | ▼ −2.49% | ▼ −3.68% | $15.22 (−2.49%) |
Sep 1, 2026 4w ago | Press Release | $26.53 $15.03 | ▼ −43.35% | ▼ −43.02% | $15.22 (−42.63%) |
Aug 11, 2026 7w ago | 8-K | $26.80 $14.31 | ▼ −46.60% | ▼ −45.55% | $15.22 (−43.21%) |
Aug 4, 2026 8w ago | 8-K | $24.93 $26.53 | ▲ +6.42% | ▲ +7.02% | $15.22 (−38.95%) |
Aug 4, 2026 8w ago | Insider Cluster | $25.81 $25.81 | · 0.00% | ▲ +1.24% | $15.22 (−41.03%) |
Jun 15, 2026 15w ago | Insider Cluster | $24.85 $32.03 | ▲ +28.89% | ▲ +28.69% | $15.22 (−38.75%) |
Jun 11, 2026 16w ago | Institutional Cluster | $23.98 $34.61 | ▲ +44.33% | ▲ +42.44% | $15.22 (−36.53%) |
May 5, 2026 21w ago | Press Release | $25.93 $22.41 | ▲ +13.57% | ▲ +16.36% | $15.22 (+41.30%) |
May 1, 2026 22w ago | Insider Cluster | $24.77 $22.85 | ▼ −7.75% | ▼ −13.04% | $15.22 (−38.55%) |
Apr 2, 2026 26w ago | 8-K | $22.45 $24.69 | ▲ +9.98% | ▲ +0.10% | $15.22 (−32.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access